Therapy of a cancer patient using a MEK inhibitor can be associated with a retinopathy.
MEK is mitogen-activated protein kinase kinase
Example drugs: binimetinib, trametinib, dabrafenib
Patient selection: malignant melanoma, other susceptible cancers
Onset is usually during the first month of therapy.
Clinical features:
(1) the retinopathy is usually transient and self-limiting, but it can be non-resolving
(2) the patient may present with blurred vision, which is often transient
(3) serous retinal detachment
(4) serous retinal edema
(5) retinal vein occlusion
(6) optic neuropathy
There are optical coherence tomography (OCT) criteria for diagnosis.
